Company: ELV
Filing Date: 2025-04-22
Form Type: 10-Q
Source: 0001156039-25-000057
Chunk: 42

Company: Elevance Health, Inc.
Filing Date: 2025-04-22
Form: 10-Q
Item: Item 8
Chunk 42
---
25, 2025 to shareholders of record at the close of business on June 10, 2025.Under our Board of Directors’ authorization, we maintain a common stock repurchase program. On October 15, 2024, our Audit Committee, pursuant to authorization granted by the Board of Directors, authorized an $8,000 increase to the common stock repurchase program. No duration has been placed on the common stock repurchase program, and we reserve the right to discontinue the program at any time. Repurchases may be made from time to time at prevailing market prices, subject to certain restrictions on volume, pricing and timing. The repurchases are effected from time to time in the open market, through negotiated transactions, including accelerated share repurchase agreements, and through plans designed to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Our stock repurchase program is discretionary, as we are under no obligation to repurchase shares. We repurchase shares under the program when we believe it is a prudent use of capital. The excess cost of the repurchased shares over par value is charged on a pro rata basis to additional paid-in capital and retained earnings.A summary of common stock repurchases for the three months ended March 31, 2025 and 2024 is as follows:Three Months Ended March 31 20252024Shares repurchased2.2 1.1 Average price per share$395.78 $492.76 Aggregate cost$880 $566 Authorization remaining at the end of the period$8,420 $3,633 We expect to utilize the remaining authorized amount over a multi-year period, subject to market and industry conditions. For additional information regarding the use of capital for debt security repurchases, see Note 10, “Debt,” included in this Quarterly Report on Form 10-Q and Note 13, “Debt,” to our audited consolidated financial statements as of and for the year ended December 31, 2024 included in Part II, Item 8 of our 2024 Annual Report on Form 10-K.

-29-

13.     Accumulated Other Comprehensive (Loss) Income 

A reconciliation of the components of accumulated other comprehensive (loss) income at March 31, 2025 and 2024 is as follows:20252024Net unrealized investment (losses) gains:Beginning of period balance$(523)$(632)Other comprehensive income (loss)